FDA Inspection 1210858 — Apellis Pharmaceuticals, Inc.
The FDA completed an inspection of Apellis Pharmaceuticals, Inc. on July 14, 2023 in Waltham, MA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- July 14, 2023
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Waltham, MA (United States)
Additional Details
Risk Evaluation and Mitigation Strategies (REMS)